Prognostic Value of Peripheral Blood Parameters in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer - Scorecard - MDSpire

Prognostic Value of Peripheral Blood Parameters in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer

  • By

  • Tae-in Yoon

  • Seunghee Baek

  • Ji hyeon Lee

  • Tae Kyung Yoo

  • Jisun Kim

  • Il Yong Chung

  • Beom Seok Ko

  • Hee Jeong Kim

  • Jong Won Lee

  • Byung Ho Son

  • Sae Byul Lee

  • January 3, 2026

  • 0 min

Share

Clinical Scorecard: Prognostic Value of Peripheral Blood Parameters in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer

At a Glance

CategoryDetail
Condition
Key MechanismsInflammatory responses influencing cancer cell proliferation and angiogenesis, as evidenced by elevated NLR and PLR.
Target Population
Care Setting

Key Highlights

  • highlight_5

Guideline-Based Recommendations

Diagnosis

    Management

    • Neoadjuvant chemotherapy as part of treatment for breast cancer, including specific regimens like AC-T or TC.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Peripheral blood biomarkers such as NLR, PLR, PDW, and MPV may serve as prognostic and predictive factors for chemotherapy response.

        Clinical Best Practices

        • Utilize inflammatory markers such as NLR and PLR for prognostic assessment and integrate them into routine clinical assessments.

        References

        Original Source(s)

        Prognostic Value of Peripheral Blood Parameters in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer

        • by Tae-in Yoon, Seunghee Baek, Ji hyeon Lee, Tae Kyung Yoo, Jisun Kim, Il Yong Chung, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Sae Byul Lee

        • January 3, 2026

        Related Content

        Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease

        Vitamin D-related genetic variants as predictive biomarkers for breast cancer in Jordanian women

        Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report